IN BRIEF: PureTech's Vor in promising findings in cancer trial

PureTech Health PLC - Boston, Massachusetts-based biotechnology company - Founded entity Vor Bio, ...

Alliance News 6 September, 2024 | 5:07PM
Email Form Facebook Twitter LinkedIn RSS

PureTech Health PLC - Boston, Massachusetts-based biotechnology company - Founded entity Vor Bio, a clinical stage cell and genome engineering company, has received new clinical data from ongoing Phase 1/2 VBP101 study. The study looks at patients with relapsed or refractory acute myeloid leukaemia receiving trem-cel followed by the Mylotarg drug. Recent data demonstrated reliable engraftment, shielding from Mylotarg on-target toxicity, a broadened Mylotarg therapeutic window, and early evidence of patient benefit.

Current stock price: 148.60 pence

12-month change: down 25%

By Eric Cunha, Alliance News news editor

Comments and questions to newsroom@alliancenews.com

Copyright 2024 Alliance News Ltd. All Rights Reserved.

Email Form Facebook Twitter LinkedIn RSS

Securities Mentioned in Article

Security Name Price Change (%) Morningstar
Rating
PureTech Health PLC 154.80 GBX -1.02 -

About Author

Alliance News

Alliance News provides Morningstar with continuously updating coverage of news affecting listed companies.

© Copyright 2024 Morningstar, Inc. All rights reserved.

Terms of Use        Privacy Policy        Modern Slavery Statement        Cookie Settings        Disclosures